Post-Traumatic Stress Disorder (PTSD) Treatment Market Analysis – Size, Share, and Forecast 2023 to 2033

The global post-traumatic stress disorder (PTSD) treatment market is expected to garner market value of USD 16.8 billion in 2023 and is expected to accumulate a market value of USD 27.37 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. Growth of the post-traumatic stress disorder (PTSD) treatment market can be attributed to the innovation of therapies along with growing prevalence of the ailment. The market for post-traumatic stress disorder (PTSD) treatment registered a CAGR of 3.3% in the historical period 2018 to 2022

Post-Traumatic Stress Disorder (PTSD) treatment is a type of therapy that is used to help people who have experienced a traumatic event and are struggling with the aftermath. PTSD is a mental health condition that can occur after a person experiences or witnesses a traumatic event such as a natural disaster, combat, sexual assault, or a serious accident.

Data Points Key Statistics
Expected Market Value (2023) USD 16.8 billion
Anticipated Forecast Value (2033) USD 27.37 billion
Projected Growth Rate (2023 to 2033) 5% CAGR

2018 to 2022 PTSD Treatment Sales Outlook Compared to Forecast from 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for post-traumatic stress disorder (PTSD) treatment reflected a value of 3.3% during the historical period, 2018 to 2022. Several factors have contributed to this growth, including increasing awareness of PTSD and mental health issues, growing demand for mental health services, and the development of new and innovative treatments for PTSD.

In recent years, there has been a significant focus on the development of new treatments for PTSD, including non-pharmacological therapies such as psychotherapy and virtual reality therapy. The growing adoption of these therapies, along with the increasing availability of pharmacological treatments, is driving the growth of the PTSD treatment market. Thus, the market for post-traumatic stress disorder (PTSD) treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.

Key Drivers Supporting the PTSD Treatment Industry

Growing awareness about mental health contributing to market growth of PTSD treatment

The rising incidence of PTSD due to traumatic events such as natural disasters, terrorist attacks, and armed conflicts is a major driver of the PTSD treatment market. According to the National Institute of Mental Health, an estimated 7.7 million adults in the United States have PTSD.

The growing awareness about mental health and the importance of seeking treatment for mental health conditions is driving the demand for PTSD treatment. People are becoming more aware of the importance of seeking help and support for mental health issues, including PTSD. The development of new and innovative therapies and technologies for the treatment of PTSD, such as virtual reality therapy, is driving the growth of the PTSD treatment market. These new therapies offer alternative treatment options for people with PTSD.

The growing demand for personalized medicine and targeted therapies is driving the development of new PTSD treatments that are tailored to the individual needs of patients. Governments around the world are increasing their support for mental health programs and initiatives, which is driving the growth of the PTSD treatment market. Governments are investing in mental health research and treatment programs to improve the quality of life for people with PTSD.

Availability of treatment and therapies favoring growth of the PTSD market growth

Psychotherapy: Psychotherapy is a type of talk therapy that is used to help people with PTSD. There are several types of psychotherapy that can be used to treat PTSD, including cognitive behavioral therapy (CBT), prolonged exposure therapy, and eye movement desensitization and reprocessing (EMDR).

Medication: Medication can be used to help manage symptoms of PTSD such as depression, anxiety, and insomnia. Common medications used to treat PTSD include antidepressants, anti-anxiety medications, and sleep aids.

Self-help strategies: There are several self-help strategies that can be used to manage symptoms of PTSD, such as exercise, relaxation techniques, and mindfulness meditation.

Support groups: Support groups can provide a sense of community and understanding for people with PTSD. Group therapy can also be helpful in providing a safe and supportive environment for people to share their experiences and learn coping strategies.

Challenges Restraining Growth in the PTSD Treatment Market

Stigma associated with mental illness and limited access to mental health services

There is still a stigma associated with mental illness, including PTSD, which can prevent people from seeking help and accessing treatment. Many people with PTSD face barriers to accessing mental health services, including limited availability of mental health professionals, lack of insurance coverage, and long wait times for appointments.

PTSD is a complex condition that is not fully understood, which can make it challenging to develop effective treatments. There is still much to learn about the underlying causes and mechanisms of PTSD. There is no consensus on the best approach to treating PTSD, and different therapies and treatments may be more effective for different people. This can make it challenging to develop standardized treatment guidelines.

The cost of PTSD treatment can be high, particularly for individuals who do not have insurance coverage or access to affordable mental health services. This can be a barrier to accessing treatment for many people. Adherence to treatment can be a challenge for people with PTSD, particularly given the complexity of the condition and the long-term nature of treatment. Many people with PTSD may struggle to stick to a treatment plan, which can impact the effectiveness of treatment.

Top Regions Advancing PTSD Diagnosis, Therapy Access, and Patient Support

Increasing Demand for Mental Health Services In North America Creating Lucrative Opportunities for PTSD Market?

Growing awareness of the importance of mental health bolstering demand for treatments for PTSD

North America is a significant market for Post-Traumatic Stress Disorder (PTSD) treatment, driven by the high prevalence of PTSD in the region and the growing demand for mental health services. The United States and Canada are the major contributors to the PTSD treatment market in North America.

In the United States, PTSD affects an estimated 8 million adults every year, and the condition is more prevalent among veterans, first responders, and survivors of sexual assault or domestic violence. The growing awareness of the importance of mental health, increased government funding for mental health programs, and a rise in the number of mental health professionals are some of the factors driving the growth of the PTSD treatment market in the United States.

Canada is also a significant market for PTSD treatment, with an estimated 10% of Canadians experiencing PTSD at some point in their lives. The Canadian government has made mental health a priority, and there has been an increase in funding for mental health programs and services. The growing demand for mental health services and the availability of innovative therapies such as virtual reality therapy are driving the growth of the PTSD treatment market in Canada.

Overall, the North America PTSD treatment market is expected to grow due to the high prevalence of PTSD, growing awareness of mental health issues, increasing government support, and the availability of innovative therapies. Thus, the North America is expected to possess a 43% market share for PTSD market in 2023.

Increasing Government Funding for Mental Health Programs Boosting Growth for PTSD Market in Europe?

Availability of innovative therapies shaping landscape for PTSD market in Europe

Europe is a significant market for Post-Traumatic Stress Disorder (PTSD) treatment, driven by the high prevalence of PTSD in the region and the increasing demand for mental health services. The major contributors to the PTSD treatment market in Europe are the United Kingdom, Germany, France, Italy, and Spain.

In the United Kingdom, PTSD affects an estimated 4% of the population, with higher rates among military personnel and emergency responders. The growing awareness of the importance of mental health, increasing government funding for mental health programs, and the availability of innovative therapies such as Eye Movement Desensitization and Reprocessing (EMDR) are some of the factors driving the growth of the PTSD treatment market in the United Kingdom.

Germany is also a significant market for PTSD treatment, with an estimated 5% of the population experiencing PTSD at some point in their lives. The German government has made mental health a priority, and there has been an increase in funding for mental health programs and services. The growing demand for mental health services and the availability of innovative therapies such as cognitive-behavioral therapy (CBT) and exposure therapy are driving the growth of the PTSD treatment market in Germany. Thus, Europe is expected to possess a 42% market share for PTSD market in 2023.

PTSD Treatment Industry Analysis by Drug Class, Therapy Type, and End User

Availability of Multiple Antidepressants Increasing Use for PTSD Treatment?

Efficiency of antidepressants commercializing the use of same for PTSD treatment

Antidepressants are often prescribed for PTSD because they can help alleviate symptoms such as depression, anxiety, and sleep disturbances. They work by regulating levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which can be imbalanced in people with PTSD. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed type of antidepressants for PTSD.

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants for PTSD. They work by increasing the levels of serotonin in the brain, which can improve mood, reduce anxiety and improve sleep patterns. Some commonly prescribed SSRIs for PTSD include fluoxetine, paroxetine, and sertraline.

Other types of antidepressants, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) may also be used in some cases. Thus, antidepressants are expected to possess a 41% market share for PTSD market in 2023.

Leading Companies in the PTSD Treatment Market

Key players in the post-traumatic stress disorder (PTSD) treatment market are Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova

  • Jazz Pharmaceuticals has developed a medication called JZP-386, which is currently being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). JZP-386 is a sodium oxybate-based investigational medication that is being studied for its ability to improve sleep quality and reduce PTSD symptoms.
  • Aptinyx is a biopharmaceutical company that has developed a medication called NYX-783, which is currently being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). NYX-783 is a small molecule drug that targets the NMDA receptor system in the brain, which is thought to be involved in the development and maintenance of PTSD symptoms.

Report Scope and Coverage for PTSD Treatment Industry

Report Attribute Details
Market Value in 2023 USD 16.8 billion
Market Value in 2033 USD 27.37 billion
Growth Rate CAGR of 5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered Drug Class, Distribution Channel, Region
Regions Covered North America; Latin America; Europe; Asia Pacific; Middle East & Africa
Key Countries Profiled United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, GCC Countries, South Africa
Key Companies Profiled Jazz Pharmaceuticals; Aptinyx; Otsuka Pharmaceutical Development & ; Commercialization, Inc.; Bionomics Limited; Merck KGaA; Pfizer Inc.; Aurobindo Pharma Limited; GlaxoSmithKline plc; Viatris Inc.; Jubilant Pharmova
Customization Available Upon Request

Top Investment Segments in the PTSD Treatment Industry Survey

By Drug Class:

  • Antidepressants
  • Anti-anxiety Drugs
  • Antipsychotics
  • Other Drug Classes

By Distribution Channel:

  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Content

  • 1. Executive Summary | Post-Traumatic Stress Disorder (PTSD) Treatment Market
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
    • 5.1. Antidepressants
    • 5.2. Anti-anxiety Drugs
    • 5.3. Antipsychotics
    • 5.4. Other Drug Classes
  • 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    • 6.1. Hospital Pharmacies
    • 6.2. Retail Pharmacies
    • 6.3. Online Pharmacies
  • 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    • 7.1. North America
    • 7.2. Latin America
    • 7.3. Europe
    • 7.4. Asia Pacific
    • 7.5. Middle East and Africa
  • 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 13. Key Countries Market Analysis
  • 14. Market Structure Analysis
  • 15. Competition Analysis
    • 15.1. Jazz Pharmaceuticals
    • 15.2. Aptinyx
    • 15.3. Otsuka Pharmaceutical Development & Commercialization, Inc.
    • 15.4. Bionomics Limited
    • 15.5. Merck KGaA
    • 15.6. Pfizer Inc.
    • 15.7. Aurobindo Pharma Limited
    • 15.8. GlaxoSmithKline plc
    • 15.9. Viatris Inc.
    • 15.10. Jubilant Pharmova
  • 16. Assumptions & Acronyms Used
  • 17. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

List of Figures

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: Middle East and Africa Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 83: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 84: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 85: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: Middle East and Africa Market Attractiveness by Drug Class, 2023 to 2033

Figure 89: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Frequently Asked Questions

What is the Current Market Valuation?

The post-traumatic stress disorder (PTSD) treatment market is valued at USD 16.8 billion in 2023.

What is the Expected Market Growth Rate in 2033?

Until 2033, the market is likely to experience a 5% CAGR.

How Big will the Post-Traumatic Stress Disorder (PTSD) Treatment Market?

The market is expected to reach USD 27.37 billion in 2033.

How is the Historical Performance of the Market?

From 2018 to 2022, the market registered a CAGR of 3.3%.

Who are the Leading Companies in the Market?

GlaxoSmithKline plc, Viatris Inc., and Jubilant Pharmova are the leading companies in the market.

Explore Similar Insights

Future Market Insights

Post-Traumatic Stress Disorder (PTSD) Treatment Market